In a major milestone in the global effort to curb HIV infections, the World Health Organization (WHO) has recommended Lenacapavir (LEN) — a long-acting injectable pre-exposure prophylaxis (PrEP) drug — as a new prevention method. This announcement was made during the 13th International AIDS Society (IAS) Conference held in Kigali, Rwanda.
The recommendation marks a historic moment in the evolution of HIV prevention tools. For the first time, people at high risk of contracting HIV have access to a biannual injection that offers strong, sustained protection — a much-needed alternative to daily oral PrEP pills.
And Kenya is leading the way.
🇰🇪 Kenya Among First Nations to Roll Out Lenacapavir
Kenya has been named among the first countries globally to unveil the revolutionary Lenacapavir PrEP program. According to the Kenyan Ministry of Health, the injectable will be available starting January 2026 under the National AIDS and STI Control Programme (NASCOP).
The rollout will occur in phases across:
- Select public hospitals
- Community health clinics
- Potentially even registered pharmacies
Access to Lenacapavir will require a routine HIV test, conducted with rapid diagnostic kits to streamline the screening process and ensure that only HIV-negative individuals receive the drug.
💉 What Is Lenacapavir — And How Does It Work?
Lenacapavir is an antiretroviral medication designed for HIV-negative individuals who are at high risk of contracting the virus. It falls under a new class of drugs known as capsid inhibitors, which disrupt the HIV virus’s ability to replicate and spread in the body.
Unlike current oral PrEP pills like Truvada or Descovy, which must be taken daily, Lenacapavir is administered as an injection just twice a year — once every six months.
This low-frequency dosing is not only more convenient but also significantly increases the likelihood of treatment adherence.
👥 Who Stands to Benefit Most?
Kenya’s HIV response has long focused on key populations, many of whom struggle to stick to daily medication routines due to stigma, poverty, or logistical barriers. Lenacapavir could be a game-changer for:
- Sex workers
- People who inject drugs
- Adolescents and young adults in high-prevalence areas
- Men who have sex with men (MSM)
- Individuals in serodiscordant relationships (where one partner is HIV-positive and the other is negative)
- Mobile populations, such as truck drivers, migrant workers, and people who travel frequently
📊 The Global HIV Burden — Why This Matters
According to WHO data, 1.3 million new HIV infections were recorded in 2024 alone. Of the 40.8 million people living with HIV worldwide, 65% are in Africa, with young people, especially women, accounting for a large proportion of new infections.
In Kenya:
- An estimated 1.4 million people are living with HIV
- About 20,000 new infections occur each year
- Adherence to daily PrEP remains a major barrier, especially among youth
Lenacapavir provides a viable solution to these challenges. It bypasses the need for daily reminders, pill boxes, or discreet storage, all of which contribute to poor adherence and high dropout rates.
🌍 A Public Health and Social Shift
Beyond its medical advantages, Lenacapavir also carries important social benefits:
- Reduced stigma: A twice-yearly injection is much less visible than daily pills, which can unintentionally “out” someone as being at risk of HIV.
- Discreet protection: The injection can be taken at a clinic without anyone knowing it’s for HIV prevention.
- Improved privacy: Particularly for teenagers and young adults living with parents or in conservative communities.
Dr. Francis Kuria of NASCOP noted:
“This drug will revolutionize the way we offer HIV prevention. It’s not just more effective — it’s also more human-centered.”
💬 What Experts Are Saying
Dr. Meg Doherty, WHO’s Director of Global HIV, Hepatitis, and STIs Programmes, said during the IAS Conference:
“Long-acting PrEP options like Lenacapavir are essential if we are to meet our global targets to reduce new infections. This is a bold step forward.”
Local Kenyan advocates, including organizations like LVCT Health and Kenya AIDS NGOs Consortium (KANCO), have welcomed the move, emphasizing that community outreach and awareness will be vital to ensure uptake.
🛣️ What Happens Next in Kenya?
From now until January 2026, NASCOP will:
- Train healthcare providers on administering Lenacapavir safely
- Design communication campaigns to inform high-risk groups
- Equip facilities with the necessary cold-chain and storage systems
- Conduct phased pilot tests in high-prevalence counties like Kisumu, Nairobi, Mombasa, and Homa Bay
The government is also exploring partnerships with civil society and private pharmacies to expand access, especially in rural and informal urban settlements.
🧭 Looking Ahead: A Turning Point in HIV Prevention
Lenacapavir isn’t just a new drug — it represents a shift in how we think about prevention. It offers freedom from the daily burden of pill-taking, a pathway toward greater confidentiality, and a powerful tool for Kenya to reduce its new HIV infections.
For those most at risk — and least served by current solutions — this could be the breakthrough they’ve been waiting for.
✅ Summary: Why Lenacapavir Matters
| Feature | Details |
|---|---|
| Drug Type | Long-acting injectable PrEP |
| Name | Lenacapavir (LEN) |
| Dosing | One injection every 6 months |
| Target Group | HIV-negative individuals at high risk |
| Kenya Rollout | January 2026 (NASCOP-led) |
| Advantages | Better adherence, reduced stigma, convenient, discreet |
| WHO Status | Recommended as of 2025 IAS Conference |